Akari Therapeutics (AKTX) Assets Average (2012 - 2026)

Akari Therapeutics (AKTX) has 13 years of Assets Average data on file, last reported at $40.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 19.44% year-over-year to $40.9 million; the trailing twelve-month figure through Mar 2026 stood at $40.9 million (down 19.44% YoY), and the FY2025 full-year result was $49.2 million, up 79.28% from the prior year.
• Assets Average fell to $40.9 million in Q1 2026, from $46.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $50.9 million in Q2 2025 to a low of $3.6 million in Q1 2024.
• A 4-year average of $28.8 million and a median of $33.8 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 1324.46% in 2025 and retreated 19.44% in 2026, its largest moves.
• Tracing AKTX's Assets Average over 4 years: stood at $12.7 million in 2022, then surged by 109.17% to $26.6 million in 2024, then jumped by 75.0% to $46.6 million in 2025, then slipped by 12.32% to $40.9 million in 2026.
• Business Quant data shows AKTX's Assets Average at $40.9 million in Q1 2026, $46.6 million in Q4 2025, and $48.1 million in Q3 2025.